CASP3 and hepatocellular carcinoma: We found that inactivation of GSK-3β by tideglusib could significantly shrink tumor (22.3% inhibition), inhibit Ki-67 expression (14.2%) and induce caspase 3 activation (9.1%), further supporting that overexpression of GSK-3β might be a tumor promoter in HCC (Fig. 7A and B).